Threonine (Amino Acid) : Physiology, Evidence, and Clinical Translation

Threonine: The Essential Amino Acid at the Crossroads of Mucosal Integrity, Protein Synthesis, and One-Carbon Metabolism

Threonine is an essential amino acid that bears a secondary alcohol group on its side chain, a structural feature that distinguishes it from its close structural analog serine and that dictates its unique and irreplaceable metabolic roles. It cannot be synthesized by mammals. It must be obtained from the diet, and its availability is a rate-limiting factor for the synthesis of intestinal mucins, the maintenance of the gut barrier, the post-translational modification of proteins via O-linked glycosylation, and the generation of glycine and one-carbon units through its degradative pathway. Threonine is the most abundant amino acid in the mucus layer that lines the gastrointestinal tract, and its consumption by the intestine is disproportionately high relative to its abundance in dietary protein. This monograph is written for the reader who seeks to understand why threonine, often overshadowed by the branched-chain amino acids and glutamine in clinical nutrition, is increasingly recognized as a conditionally limiting amino acid for mucosal homeostasis, immune competence, and the metabolic adaptation to injury and infection. We dissect the mechanisms that make threonine a uniquely intestinal amino acid, grade the evidence that supports its therapeutic use, and map the clinical contexts in which threonine status may be a modifiable determinant of outcome.

---

Part 1. The Structural and Metabolic Identity of Threonine

Threonine is an alpha-amino acid with the chemical formula C4H9NO3. Its side chain is a 1-hydroxyethyl group, a secondary alcohol attached to the alpha carbon. This structure gives threonine two chiral centers, and the naturally occurring L-threonine is the (2S,3R) diastereomer. The secondary alcohol distinguishes threonine from serine, which bears a primary alcohol, and from valine, which is a purely aliphatic branched-chain amino acid. The hydroxyl group is the functional moiety that participates in O-linked glycosylation, the covalent attachment of N-acetylgalactosamine to the oxygen atom of the side chain, a modification that initiates the synthesis of mucin-type glycoproteins.

1A. The Biosynthetic Impossibility: Why Threonine Is Essential

Humans lack the enzymes required to synthesize threonine de novo. In plants and microorganisms, threonine is synthesized from aspartate via a pathway that involves aspartokinase, aspartate semialdehyde dehydrogenase, homoserine dehydrogenase, homoserine kinase, and threonine synthase. This pathway is absent in animals. Threonine is therefore an essential amino acid that must be supplied by the diet. The daily requirement for an adult is approximately 15 to 20 milligrams per kilogram of body weight, corresponding to approximately 1 to 1.5 grams per day for a 70-kilogram individual. The requirement is higher during growth, pregnancy, lactation, and recovery from injury or illness. Dietary sources rich in threonine include meat, poultry, fish, eggs, dairy products, legumes, and nuts. Cereal grains are relatively poor sources, and diets heavily dependent on cereals may be marginal in threonine content.

1B. The Degradative Pathways: Glycine, Acetyl-CoA, and Methylglyoxal

Threonine is degraded by three distinct enzymatic pathways, each with different metabolic outcomes.

The dominant pathway is the threonine dehydrogenase pathway, which is active in the liver and, to a lesser extent, in other tissues. Threonine dehydrogenase oxidizes threonine to 2-amino-3-ketobutyrate, which is then cleaved by 2-amino-3-ketobutyrate coenzyme A ligase to yield glycine and acetyl-CoA. This is a major source of glycine, particularly in the liver, and it links threonine catabolism to the glycine-dependent pathways of glutathione synthesis, heme synthesis, creatine synthesis, and one-carbon metabolism via the glycine cleavage system. The acetyl-CoA produced enters the tricarboxylic acid cycle or is used for fatty acid synthesis. This pathway accounts for approximately 60 to 80 percent of threonine catabolism in humans.

The second pathway is threonine dehydratase, which converts threonine to alpha-ketobutyrate and ammonia. Alpha-ketobutyrate is then oxidatively decarboxylated to propionyl-CoA, which enters the tricarboxylic acid cycle via succinyl-CoA. This pathway is quantitatively minor in humans under normal conditions but may be upregulated in states of threonine excess.

The third pathway is the aldolase pathway, catalyzed by threonine aldolase, which cleaves threonine to glycine and acetaldehyde. The acetaldehyde is then oxidized to acetate. This pathway is active in the intestine and may contribute to the high rate of threonine utilization by the gut.

A non-enzymatic consequence of threonine metabolism, and of threonine supplementation at high doses, is the formation of methylglyoxal, a reactive dicarbonyl species. The glycine and acetyl-CoA produced by the threonine dehydrogenase pathway can condense non-enzymatically, or be converted via aminoacetone, to methylglyoxal. Methylglyoxal is a potent glycating agent that modifies proteins and DNA, forming advanced glycation end-products (AGEs). The body detoxifies methylglyoxal through the glyoxalase system, which requires glutathione. This creates a metabolic tension: threonine is a precursor for glutathione synthesis via its conversion to glycine, but its degradation also generates a substrate that consumes glutathione. The net effect of threonine loading on oxidative stress and glycation has not been adequately characterized in humans.

---

Part 2. The Intestinal Biology of Threonine: Mucins, Barrier Function, and the Gut-Immune Axis

The most distinctive feature of threonine biology is its disproportionate utilization by the intestine. The portal-drained viscera, the intestine, pancreas, and spleen, extract a much larger fraction of dietary threonine than of any other essential amino acid. In piglets, a well-established model of human neonatal intestinal physiology, the intestine extracts approximately 60 percent of dietary threonine on the first pass, compared to 30 percent for lysine and 20 percent for leucine. This is not a metabolic inefficiency. It reflects the high demand for threonine in the synthesis of mucins, the glycoproteins that form the protective mucus layer overlying the intestinal epithelium.

2A. Mucin Structure and the Threonine Requirement

Mucins are a family of high-molecular-weight glycoproteins that are secreted by goblet cells (secreted mucins, primarily MUC2 in the intestine) or anchored to the apical membrane of enterocytes (membrane-bound mucins, including MUC1, MUC3, and MUC4). MUC2 is the major structural component of the intestinal mucus layer. It is a massive, heavily glycosylated protein that polymerizes via disulfide bonds to form a gel-like network that serves as a physical barrier, a matrix for antimicrobial peptides, and a habitat for the commensal microbiota.

The MUC2 protein core contains a central region of tandem repeats rich in proline, threonine, and serine, the so-called PTS domain. Threonine and serine residues in this domain are the sites of O-linked glycosylation, in which N-acetylgalactosamine is attached to the hydroxyl oxygen, followed by the addition of galactose, N-acetylglucosamine, and terminal sugars including sialic acid and fucose. The glycosylation of MUC2 is essential for its function: the carbohydrate chains bind water, giving the mucus its gel-like properties, and they provide binding sites for commensal bacteria and decoy receptors for pathogens. Threonine accounts for approximately 25 to 30 percent of the amino acid composition of the MUC2 tandem repeat domain, making it the most abundant amino acid in the protein.

The biosynthetic demand for threonine in mucin synthesis is substantial. The intestinal mucus layer is continuously synthesized, secreted, and degraded, with a turnover time measured in hours to days. The goblet cells of the small and large intestine synthesize MUC2 at a rate that, on a per-gram basis, rivals the rate of albumin synthesis by the liver. When threonine availability is limiting, MUC2 synthesis is impaired. In animal models, threonine deficiency reduces the thickness of the intestinal mucus layer, decreases the density of goblet cells, and alters the glycosylation profile of secreted mucins. The functional consequence is an increase in intestinal permeability, an enhanced susceptibility to enteric infection, and a shift in the composition of the gut microbiota.

2B. The Gut-Immune Axis and Threonine-Dependent Barrier Function

The intestinal barrier is a composite of the mucus layer, the enterocyte monolayer with its tight junctions, and the underlying immune cells of the lamina propria. Threonine influences each of these components. The mucus layer, dependent on threonine for its synthesis, is the first line of defense. When the mucus layer is thinned or its composition is altered, luminal bacteria and their products, including lipopolysaccharide, gain access to the enterocyte surface. This triggers an innate immune response, with the activation of toll-like receptors and the secretion of pro-inflammatory cytokines. Chronic, low-grade activation of this pathway is a contributor to the systemic inflammation that accompanies metabolic syndrome, inflammatory bowel disease, and critical illness.

Threonine also supports the synthesis of secretory immunoglobulin A (sIgA), the immunoglobulin that is transcytosed across the enterocyte and secreted into the mucus layer, where it neutralizes pathogens and toxins. The plasma cells that produce IgA in the lamina propria require amino acids for immunoglobulin synthesis, and threonine is abundant in the hinge region of IgA, where O-linked glycosylation occurs. The glycosylation of IgA is important for its resistance to bacterial proteases and for its interaction with the polymeric immunoglobulin receptor that mediates its transport across the epithelium.

In the enterocyte itself, threonine supports the synthesis of tight junction proteins, including occludin and the claudins, that regulate paracellular permeability. The tight junction complex is a multi-protein assembly that seals the intercellular space between enterocytes, preventing the uncontrolled passage of luminal contents into the lamina propria. Threonine is a component of these proteins, and its availability can influence their synthesis, though the data on this point are less extensive than for mucin synthesis.

2C. Threonine and the Intestinal Microbiota

The mucus layer is not merely a barrier; it is a metabolic niche for the commensal microbiota. Specific bacterial species, including Akkermansia muciniphila and members of the Bacteroides genus, possess the enzymatic machinery to degrade mucin glycans and use them as a carbon and energy source. The provision of mucin-derived glycans to these bacteria is a form of host-microbial symbiosis: the host feeds the bacteria that, in turn, produce short-chain fatty acids, including butyrate, that nourish the enterocyte and modulate the immune response. A threonine deficit that impairs mucin synthesis alters the substrate supply to the mucin-degrading microbiota, potentially shifting the composition of the gut microbiome in a direction that is less favorable to the host. In animal models, threonine supplementation alters the composition of the gut microbiome, increasing the abundance of beneficial bacteria and reducing the abundance of potential pathogens. The translation of these findings to human gut ecology is a developing area of research.

---

Part 3. The Systemic Biology of Threonine

Beyond the intestine, threonine contributes to several systemic functions that are clinically significant.

3A. O-Linked Glycosylation and Systemic Mucin Production

The O-linked glycosylation of proteins with N-acetylgalactosamine attached to serine or threonine residues is not confined to the intestine. The mucin family of glycoproteins is expressed throughout the body: MUC1 on the apical surface of epithelial cells in the respiratory tract, the genitourinary tract, and the mammary gland; MUC4 in the airway epithelium and the conjunctiva of the eye; MUC5AC and MUC5B in the respiratory mucus; and MUC16 on the ovarian surface and in the ocular surface. In each of these tissues, threonine is required for the synthesis of the mucin protein core. A systemic threonine deficiency could, in theory, impair the protective mucus layer in the lungs, the eyes, the reproductive tract, and other mucosal surfaces. The clinical evidence for this is limited, but the mechanistic logic is identical to that in the intestine.

3B. Threonine as a Glycine Precursor

The threonine dehydrogenase pathway produces glycine. In the liver, threonine is a quantitatively significant source of glycine, and the flux through this pathway contributes to the glycine pools required for glutathione synthesis, heme synthesis, creatine synthesis, and one-carbon metabolism. The metabolic relationship between threonine and glycine is bidirectional. Threonine can supply glycine through its degradation, and glycine can partially spare threonine by reducing the demand for threonine-derived glycine. In conditions of high glycine demand, such as pregnancy, wound healing, or chronic inflammation, the contribution of threonine to the glycine pool may become more significant, and a threonine deficit may exacerbate a concurrent glycine deficit. This interaction has not been directly studied in humans.

3C. Threonine, mTORC1, and Protein Synthesis

Like other essential amino acids, threonine is an activator of the mTORC1 signaling pathway that drives protein synthesis and cell growth. The specific contribution of threonine to mTORC1 activation, independent of the other essential amino acids, has not been as extensively characterized as that of leucine, arginine, or asparagine. However, the general principle that an essential amino acid deficiency attenuates mTORC1 activity applies to threonine. In states of threonine deficiency, the capacity for protein synthesis in all tissues, not just the intestine, is constrained.

3D. Immunological Competence

The immune system's requirement for amino acids during a proliferative response is substantial. Lymphocyte proliferation, immunoglobulin synthesis, and the production of acute-phase proteins by the liver all demand a supply of amino acids, including threonine. The glycosylation of immunoglobulins, particularly IgA and IgG, involves O-linked glycosylation at threonine residues in the hinge region, and the functional properties of these antibodies are influenced by their glycosylation state. A threonine deficit could impair the quality and quantity of the humoral immune response. In animal models, threonine supplementation enhances the antibody response to vaccination and improves resistance to enteric pathogens. Human data on threonine and immune function are limited to observational studies in malnourished populations, where threonine supplementation, as part of a comprehensive nutritional intervention, improves outcomes from infectious diseases.

---

Part 4. The Clinical Taxonomy of Threonine Insufficiency

Threonine deficiency, like other essential amino acid deficiencies, is rare in isolation. It occurs in the context of generalized protein-energy malnutrition or in specific clinical conditions that disproportionately increase threonine demand or loss.

4A. Absolute Dietary Deficiency

Isolated threonine deficiency from a diet that is otherwise adequate in protein does not occur in humans. Diets that are deficient in threonine are deficient in total protein, and the clinical presentation is that of protein-energy malnutrition: stunting, wasting, impaired immune function, and increased susceptibility to infection. The specific contribution of threonine deficiency to this phenotype cannot be separated from the deficiency of other amino acids, but the intestinal manifestations of protein-energy malnutrition, including villous atrophy, increased intestinal permeability, and bacterial translocation, are consistent with a threonine deficit.

4B. Pathological Loss and Malabsorption

Conditions that increase the loss of endogenous proteins from the gastrointestinal tract impose a drain on the threonine pool. In protein-losing enteropathy, which can occur in inflammatory bowel disease, celiac disease, intestinal lymphangiectasia, and after the Fontan procedure for congenital heart disease, plasma proteins, including albumin and immunoglobulins, are lost into the intestinal lumen. The liver increases its synthesis of these proteins to compensate, increasing the demand for amino acids, including threonine. The combination of intestinal protein loss and increased hepatic protein synthesis creates a state of high threonine turnover that may not be met by dietary intake, particularly if the underlying disease also impairs appetite or absorption.

In severe burn injury, the exudative loss of protein from the wound surface can be massive, and the metabolic response to burn injury includes a sustained hypercatabolic state with accelerated proteolysis and increased hepatic synthesis of acute-phase proteins. Threonine requirements in this context are significantly elevated above those of healthy individuals, and standard nutritional support may not provide adequate threonine to meet the combined demands of wound healing, immune function, and intestinal mucosal maintenance.

4C. Kinetic Insufficiency of the Intestinal Mucosa

The most clinically relevant form of threonine insufficiency is a kinetic deficit that is specific to the intestine. In conditions where the intestinal demand for threonine is elevated, systemic threonine status may be normal, as assessed by a fasting plasma level, but the availability of threonine for mucin synthesis within the enterocyte and goblet cell is insufficient. This is a functional, tissue-specific deficit. It occurs in the context of intestinal inflammation, where goblet cell hyperplasia and increased mucin secretion are part of the reparative response, and in the context of parenteral nutrition, where the intestine is bypassed and the luminal supply of threonine is absent.

The intestinal atrophy that accompanies prolonged parenteral nutrition is well-recognized, and the absence of enteral nutrients, including threonine, is a contributing factor. The provision of enteral threonine, even in small amounts that do not contribute significantly to systemic nutrition, can support the maintenance of the intestinal mucosa in patients who are otherwise dependent on parenteral nutrition. This is the concept of minimal enteral nutrition or trophic feeding, and threonine is one of the amino acids that mediates this effect.

---

Part 5. The Evidence Mapped by Quality and Clinical Application

The clinical evidence for threonine supplementation is less extensive than that for the amino acids discussed earlier in this series. The most robust data are in animal models, with human studies limited to specific clinical contexts.

5.1. Threonine in Parenteral and Enteral Nutrition

The inclusion of threonine in parenteral and enteral nutrition formulations is based on its status as an essential amino acid. The standard amino acid solutions used in parenteral nutrition contain threonine at concentrations that are designed to meet the requirements of healthy adults. The adequacy of these standard formulations for patients with elevated threonine requirements, including those with burns, trauma, or intestinal protein loss, has been questioned but not definitively studied. Some specialized enteral nutrition formulas for critically ill patients and for patients with inflammatory bowel disease contain higher concentrations of threonine, based on the rationale that threonine supports intestinal barrier function and immune competence. The evidence for a clinical benefit of threonine-enriched formulas over standard formulas is limited to small studies and expert opinion, not to large, randomized trials with hard endpoints.

5.2. Threonine Supplementation in Inflammatory Bowel Disease

Animal models of colitis consistently show that threonine supplementation reduces intestinal inflammation, improves mucosal healing, and restores the integrity of the mucus layer. The translation to human inflammatory bowel disease has been limited. A small pilot study in patients with ulcerative colitis found that threonine supplementation at 2 grams per day for 12 weeks was safe and well-tolerated, but the study was not powered to detect an effect on disease activity. The theoretical rationale is strong, but the clinical evidence is insufficient to support a recommendation for threonine supplementation as a standard therapy in inflammatory bowel disease.

5.3. Threonine in Neonatal and Pediatric Nutrition

The neonatal period is one of rapid growth and intestinal development, and threonine requirements are proportionately higher than in adults. Human milk contains threonine at a concentration that supports the growth and intestinal maturation of the breastfed infant. Infant formulas are supplemented with threonine to match the concentrations in human milk. Preterm infants, who have missed the period of in utero threonine accretion and who have an immature intestine, have particularly high threonine requirements. The optimization of threonine content in preterm infant formulas and in parenteral nutrition for preterm infants is an active area of research, with the goal of supporting growth, intestinal development, and neurodevelopment without exceeding the capacity for threonine degradation and risking methylglyoxal accumulation.

5.4. Threonine and the Gut-Brain Axis

An emerging area of research is the connection between threonine, the gut microbiota, and the brain. The mucus layer supports a microbial ecosystem that produces short-chain fatty acids and other metabolites that influence brain function through the gut-brain axis. Threonine, by supporting the mucus layer, may indirectly influence brain function. Additionally, threonine is a precursor for glycine, which functions as an inhibitory neurotransmitter in the brainstem and spinal cord and as a co-agonist at the NMDA receptor. The contribution of dietary threonine to brain glycine levels has not been quantified, and the concept of modulating brain function through threonine supplementation is entirely theoretical.

---

Part 6. A Clinical Dosing Compendium

The therapeutic use of threonine is less well-defined than that of many other amino acids. The dosing strategies below are drawn from the limited human data and from the physiological principles discussed in this monograph.

6.1. Evidence-Based and Guideline-Supported Protocols

Standard Nutritional Support. In parenteral and enteral nutrition, threonine is provided as part of a balanced amino acid mixture. The standard dose is 15 to 20 milligrams per kilogram per day for adults, adjusted for the clinical condition. This is not a therapeutic supplementation protocol; it is the provision of an essential nutrient to prevent deficiency.

Infant Formula. The threonine content of standard infant formula is approximately 70 to 90 milligrams per 100 milliliters, designed to match the threonine concentration in human milk. Preterm infant formulas may contain higher concentrations. The dosing is weight-based and managed by pediatricians and neonatologists.

6.2. Theoretical and Postulated Dosing Frameworks

Intestinal Barrier Support in Inflammatory Bowel Disease. Rationale: threonine is required for mucin synthesis and the maintenance of the intestinal mucus barrier. In inflammatory bowel disease, the mucus barrier is compromised, and threonine availability may be rate-limiting for its repair. Postulate: a trial of L-threonine at 2 to 4 grams per day, in divided doses, for 12 weeks in patients with mild to moderate ulcerative colitis, as an adjunct to standard medical therapy. The primary endpoint would be the change in endoscopic or histological markers of mucosal healing. The monitoring of disease activity, including fecal calprotectin and clinical symptoms, is essential.

Peri-Surgical Intestinal Protection. Rationale: major abdominal surgery, particularly surgery involving the gastrointestinal tract, is associated with postoperative ileus, increased intestinal permeability, and bacterial translocation. Threonine, provided enterally before surgery, could theoretically support the integrity of the mucus barrier and reduce postoperative complications. Postulate: a pre-operative protocol of 3 grams of L-threonine, administered enterally three times daily for three days before elective colorectal surgery, with the primary endpoint of the time to return of bowel function and the secondary endpoint of infectious complications. The safety of enteral threonine in the perioperative period must be established, particularly in patients with bowel obstruction or severe ileus.

Burn Injury and Critical Illness. Rationale: the catabolic state after major burn injury imposes a massive demand for amino acids for wound healing, immune function, and acute-phase protein synthesis. Standard nutritional support may not provide adequate threonine. Postulate: a threonine-enriched enteral nutrition formula, providing 30 to 40 milligrams of threonine per kilogram per day, in patients with burns over more than 20 percent of body surface area, with the primary endpoint of wound healing rate and the secondary endpoint of infectious complications. This study would need to control for total protein and energy intake, as threonine is being tested as a specific supplement, not as a component of increased total nutrition.

Threonine and Mucosal Recovery After Chemotherapy. Rationale: chemotherapy, particularly agents that target rapidly dividing cells, damages the intestinal epithelium, causing mucositis, diarrhea, and increased intestinal permeability. Threonine could theoretically support the recovery of the intestinal mucosa after chemotherapy. Postulate: a trial of L-threonine at 3 grams per day, initiated at the start of a chemotherapy cycle and continued for 14 days, in patients receiving mucotoxic chemotherapy for solid tumors. The primary endpoint would be the severity and duration of oral and gastrointestinal mucositis, as assessed by validated scales.

6.3. Universal Principles Governing Threonine Supplementation

Threonine Is a Conditionally Essential Amino Acid for the Intestine. The systemic requirement for threonine can be met by a balanced diet under normal conditions. The intestinal requirement, particularly for mucin synthesis, may exceed systemic availability in conditions of intestinal injury, inflammation, or repair. The concept of a tissue-specific, conditional essentiality is central to the therapeutic rationale for threonine supplementation.

The Route of Administration Matters. For effects on the intestinal mucosa, enteral administration is required. Threonine delivered parenterally bypasses the intestine and does not directly support mucin synthesis. The intestinal utilization of threonine is driven by the luminal concentration, not the plasma concentration. This has practical implications: a patient on parenteral nutrition who requires intestinal mucosal support may benefit from a small enteral threonine supplement, even if the total nutritional requirement is being met parenterally.

The Safety of High-Dose Threonine Is Not Established. Threonine is generally recognized as safe at doses that are typical of dietary intake. The safety of chronic, high-dose threonine supplementation, above 5 grams per day, has not been established in humans. The theoretical concerns include the accumulation of methylglyoxal and the potential for glycoxidative damage if the glyoxalase system is overwhelmed. Threonine supplementation in patients with impaired renal function, where the clearance of methylglyoxal and its metabolites may be reduced, should be approached with caution.

Threonine Metabolism Is Intertwined with Glycine and Serine Status. Threonine is a glycine precursor, and its metabolism is linked to the one-carbon cycle. Supplementation with threonine should be considered in the context of overall amino acid balance, not in isolation. A patient with a concurrent glycine deficit may derive additional benefit from threonine supplementation, but a patient with adequate or high glycine intake may derive less.

---

Part 7. The Unresolved Frontier

Three questions define the current limit of threonine science.

Is Threonine the Rate-Limiting Nutrient for Intestinal Mucosal Maintenance in Humans? The animal data are compelling: threonine deficiency impairs mucin synthesis, thins the mucus layer, and increases susceptibility to intestinal injury. The translation of this finding to human intestinal physiology is the central gap. A study that directly measures intestinal mucin synthesis rates, using stable isotope-labeled threonine, in healthy humans and in patients with intestinal disease, would define the threonine requirement of the human intestine and determine whether dietary threonine intake is sufficient to meet it.

Can Threonine Supplementation Alter the Course of Inflammatory Bowel Disease? The rationale is strong, but the evidence is absent. A well-designed, randomized, placebo-controlled trial of threonine as an adjunct to standard therapy in ulcerative colitis or Crohn's disease, with endoscopic endpoints, is required to move this from a theoretical intervention to an evidence-based therapy. The dose, duration, and formulation of threonine for this indication have not been optimized.

What Is the Significance of Threonine-Derived Methylglyoxal in Vivo? The degradation of threonine generates methylglyoxal, a reactive dicarbonyl. The body's capacity to detoxify methylglyoxal via the glyoxalase system is finite, and a sustained excess of methylglyoxal production over detoxification contributes to AGE formation and tissue damage. Whether high-dose threonine supplementation, particularly in the context of impaired glyoxalase function, as occurs in diabetes and aging, results in a net increase in methylglyoxal and AGE formation has not been studied. This is a safety question that should be addressed before chronic, high-dose threonine supplementation is widely recommended.

---

Part 8. Synthesis for an Evidence-Based Approach

Threonine is an essential amino acid whose most distinctive biological role is its support of the intestinal mucus barrier. It is the most abundant amino acid in intestinal mucins, and its consumption by the gut on first pass is disproportionately high. This positions threonine as a conditionally limiting nutrient for the maintenance of intestinal mucosal integrity, particularly in conditions where the mucus barrier is under attack or where the repair of the intestinal epithelium is a clinical priority.

The clinical evidence for threonine supplementation is less mature than that for many other nutraceuticals. The inclusion of threonine in parenteral and enteral nutrition is standard, but the use of threonine as a targeted therapeutic agent, for inflammatory bowel disease, for perioperative intestinal protection, or for the recovery from chemotherapy-induced mucositis, is supported by mechanistic rationale and animal data but not by definitive human trials. The clinician who considers threonine supplementation in these contexts must acknowledge the gap between the preclinical promise and the clinical evidence.

The safety of threonine at doses that are typical of dietary intake is established by its essentiality. The safety of chronic, high-dose threonine supplementation is not. The metabolic fate of threonine, its conversion to glycine and acetyl-CoA, and its potential to generate methylglyoxal, should give pause to the uncritical use of high-dose threonine outside of a monitored clinical context.

Threonine occupies a position in the amino acid pantheon that is defined by its specificity for the intestine. It is not a general metabolic enhancer or a systemic signaling molecule. It is a substrate for the synthesis of the mucus that separates the internal milieu from the microbial ecosystem of the gut lumen. The integrity of that barrier is a determinant of health that extends far beyond the intestine, influencing systemic inflammation, immune function, and the gut-brain axis. The investigation of threonine as a targeted agent for the preservation and restoration of the intestinal barrier is a logical extension of its known biology, and it is a frontier that merits rigorous clinical investigation.